文献速递乳腺癌

三阴性乳腺癌胚系突变状态、病理完全缓解与无病生存:GeparSixto随机临床试验的二次分析

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2017-01-01

该研究为GeparSixto随机临床试验的二次分析,纳入291例三阴性乳腺癌患者,检测BRCA1/BRCA2等胚系突变,比较卡铂与非卡铂组的病理完全缓解(pCR)率。结果显示卡铂组pCR率为56.8%(83/146),非卡铂组为41.4%(60/145),OR 1.87(95%CI 1.17-2.97,P=.009)。在非卡铂组中,BRCA1/BRCA2突变携带者pCR率为66.7%(16/24),无突变者为36.4%(44/121),OR 3.50(95%CI 1.39-8.84,P=.008);突变携带者加用卡铂后pCR率未进一步提高(17/26,65.4%),而无突变者加用卡铂后pCR率提高至55%(66/120)vs 36.4%(44/121),OR 2.14(95%CI 1.28-3.58,P=.004)。无BRCA1/BRCA2突变者加用卡铂后无病生存率亦提高(73.5% vs 85.3%,HR 0.53,95%CI 0.29-0.96,P=.04)。

要点

  • 卡铂组pCR率56.8%(83/146)vs 非卡铂组41.4%(60/145),OR 1.87(95%CI 1.17-2.97,P=.009)。
  • 非卡铂组中BRCA1/BRCA2突变者pCR率66.7%(16/24)vs 无突变者36.4%(44/121),OR 3.50(95%CI 1.39-8.84,P=.008)。
  • 无BRCA1/BRCA2突变者加用卡铂后pCR率55%(66/120)vs 36.4%(44/121),OR 2.14(95%CI 1.28-3.58,P=.004)。

核心结论

  • 在非标准化GeparSixto联合化疗方案下,无BRCA1/BRCA2胚系突变的三阴性乳腺癌患者从加用卡铂中获益,而BRCA1/BRCA2突变携带者本身缓解率较高,加用卡铂未观察到额外效应。

研究设计与样本

  • GeparSixto随机临床试验的二次分析,采用存档DNA样本和癌症家族史,纳入2011年8月1日至2012年12月31日入组的315例三阴性乳腺癌患者中的291例(92.4%),为多中心前瞻性研究。
  • 对BRCA1、BRCA2及其他16个癌症易感基因进行胚系突变分析,比较卡铂组与非卡铂组的pCR率;遗传分析在德国科隆家族性乳腺癌和卵巢癌中心进行,数据分析时间为2015年11月1日至12月31日。

主要发现

  • 291例患者均为女性,平均(SD)年龄48(11)岁;卡铂组pCR率56.8%(83/146),非卡铂组41.4%(60/145),OR 1.87(95%CI 1.17-2.97,P=.009)。
  • 致病性BRCA1/BRCA2胚系突变见于50/291例(17.2%);非卡铂组中突变携带者pCR率66.7%(16/24),无突变者36.4%(44/121),OR 3.50(95%CI 1.39-8.84,P=.008)。
  • BRCA1/BRCA2突变携带者高pCR率(16/24,66.7%)未因加用卡铂而进一步提高(17/26,65.4%)。
  • 无BRCA1/BRCA2突变者中,卡铂组pCR率55%(66/120)vs 非卡铂组36.4%(44/121),OR 2.14(95%CI 1.28-3.58,P=.004)。
  • 无致病性BRCA1/BRCA2突变者加用卡铂后无病生存率升高:非卡铂组73.5%(95%CI 64.1%-80.8%)vs 卡铂组85.3%(95%CI 77.0%-90.8%),HR 0.53(95%CI 0.29-0.96,P=.04)。

关键数值与推荐

  • pCR主要终点采用ypT0/is ypN0定义。
  • 卡铂组pCR率56.8%(83/146)vs 非卡铂组41.4%(60/145),OR 1.87(95%CI 1.17-2.97,P=.009)。
  • 非卡铂组中BRCA1/BRCA2突变者pCR率66.7%(16/24)vs 无突变者36.4%(44/121),OR 3.50(95%CI 1.39-8.84,P=.008)。
  • 无BRCA1/BRCA2突变者加用卡铂后pCR率55%(66/120)vs 36.4%(44/121),OR 2.14(95%CI 1.28-3.58,P=.004)。
  • 无致病性BRCA1/BRCA2突变者无病生存率:非卡铂组73.5%(95%CI 64.1%-80.8%)vs 卡铂组85.3%(95%CI 77.0%-90.8%),HR 0.53(95%CI 0.29-0.96,P=.04)。

临床怎么用

  • 原文结论指出,在非标准化GeparSixto联合化疗方案下,无BRCA1/BRCA2胚系突变的三阴性乳腺癌患者从加用卡铂中获益,而BRCA1/BRCA2突变携带者本身缓解率较高,加用卡铂未观察到额外效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether BRCA1 and BRCA2 germline mutation status affects treatment outcome remains elusive. OBJECTIVE: To determine whether BRCA1 and BRCA2 germline mutation status affects therapy response in patients with TNBC. DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of a randomized clinical trial used archived DNA samples and cancer family history of 315 patients with TNBC enrolled between August 1, 2011, and December 31, 2012, in the GeparSixto trial. In all, 291 participants (92.4%) were included in this multicenter prospective investigation. DNA samples were analyzed for germline mutations in BRCA1, BRCA2, and 16 other cancer predisposition genes. The pCR rates between the carboplatin and noncarboplatin arms were compared. Genetic analyses were performed at the Center for Familial Breast and Ovarian Cancer in Cologne, Germany; data analysis, November 1 through December 31, 2015. MAIN OUTCOMES AND MEASURES: Proportion of patients who achieved pCR and disease-free survival after neoadjuvant treatment according to BRCA1 and BRCA2 germline mutation status. For pCR rates, the ypT0/is ypN0 definition was used as a primary end point. RESULTS: Of the 291 patients with TNBC, all were women; the mean (SD) age was 48 (11) years. The pCR rate in the carboplatin group was 56.8% (83 of 146) and 41.4% (60 of 145) in the noncarboplatin group (odds ratio [OR], 1.87; 95% CI, 1.17-2.97; P = .009). Pathogenic BRCA1 and BRCA2 germline mutations were present in 50 of the 291 patients (17.2%). In the noncarboplatin arm, the pCR rate was 66.7% (16 of 24) for patients with BRCA1 and BRCA2 mutations and 36.4% (44 of 121) for patients without (OR, 3.50; 95% CI, 1.39-8.84; P = .008). The high pCR rate observed in BRCA1 and BRCA2 mutation carriers (16 of 24 [66.7%]) was not increased further by adding carboplatin (17 of 26 [65.4%]). In contrast, carboplatin increased response rates in patients without BRCA1 and BRCA2 mutations: 66 of the 120 patients (55%) without BRCA1 and BRCA2 mutations achieved pCR in the carboplatin arm vs 44 of the 121 patients (36.4%) in the noncarboplatin arm (OR, 2.14; 95% CI, 1.28-3.58; P = .004). Patients without pathogenic BRCA1 and BRCA2 alterations showed elevated disease-free survival rates when carboplatin was added (without carboplatin, 73.5%; 95% CI, 64.1%-80.8% vs with carboplatin, 85.3%; 95% CI, 77.0%-90.8%; hazard ratio, 0.53; 95% CI, 0.29-0.96; P = .04). CONCLUSIONS AND RELEVANCE: Under the nonstandard GeparSixto polychemotherapy regimen, patients without BRCA1 and BRCA2 germline mutations benefited from the addition of carboplatin and those with BRCA1 and BRCA2 mutations showed superior response rates without additive effects observed for carboplatin. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01426880.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Hahnen E, Lederer B, Hauke J, et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol. 2017. PMID: 28715532. doi:10.1001/jamaoncol.2017.1007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。